Results from Phase I and Phase II study indicate that Histogenics’ NeoCart® tissue-engineered implant is a safe, effective treatment for articular cartilage lesions through 5-year follow-up. Further, patient-reported outcomes demonstrated statistically significant improvement on virtually all pain and functional endpoints, as early as 3 to 6 months, with sustained outcomes through 5 years.
The publication analyzed magnetic resonance imaging data through 60 months from the Phase I and II clinical trials of NeoCart for the repair of articular cartilage injuries in the knee in 29 patients.
As of early 4Q16, the company has enrolled ~3/4 of 245 patients required to complete enrollment of an ongoing Phase III clinical trial for NeoCart, which is being conducted under a Special Protocol Assessment with FDA. This trial is designed to evaluate safety and efficacy as a first-line therapy for full thickness knee cartilage defects in skeletally mature adults vs. microfracture, the standard of care.
Results from Phase I and Phase II study indicate that Histogenics' NeoCart® tissue-engineered implant is a safe, effective treatment for articular cartilage lesions through 5-year follow-up. Further, patient-reported outcomes demonstrated statistically significant improvement on virtually all pain and functional endpoints, as early as 3 to 6...
Results from Phase I and Phase II study indicate that Histogenics’ NeoCart® tissue-engineered implant is a safe, effective treatment for articular cartilage lesions through 5-year follow-up. Further, patient-reported outcomes demonstrated statistically significant improvement on virtually all pain and functional endpoints, as early as 3 to 6 months, with sustained outcomes through 5 years.
The publication analyzed magnetic resonance imaging data through 60 months from the Phase I and II clinical trials of NeoCart for the repair of articular cartilage injuries in the knee in 29 patients.
As of early 4Q16, the company has enrolled ~3/4 of 245 patients required to complete enrollment of an ongoing Phase III clinical trial for NeoCart, which is being conducted under a Special Protocol Assessment with FDA. This trial is designed to evaluate safety and efficacy as a first-line therapy for full thickness knee cartilage defects in skeletally mature adults vs. microfracture, the standard of care.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
